Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 January 2019 | Story Charlene Stanley | Photo Charlene Stanley
Michele Middle
Michelle Middle, CMO of Farmovs, looks forward to expanding their operations after the UFS acquired 100% shareholding in 2018.

In medical research, there are NO shortcuts.

The journey of a new medicine from lab to pharmacy shelf takes on average at least 10 years.

Michelle Middle’s journey from young medical graduate starting her first job at FARMOVS to becoming the company’s Chief Medical Officer, was more than twice that long. It was a journey that systematically and adequately equipped her to now Co-captain this flagship enterprise through its biggest challenge yet.

Michelle remembers how Farmovs started in 1974 as a research centre in the Department of Pharmacology. After graduating as medical doctor, she joined Farmovs in 1993, shortly before they moved to their current extensive facilities just south of the Sasol Library.

In 2000, international Clinical Research Organization (CRO) giant Parexel acquired a 70% shareholding, and the name changed to Farmovs-Parexel.

“Parexel really invested a lot in infrastructure and technology, bringing facilities here on par with the best in the world,” says Michelle.

Her own journey in medical research took her to George and later to the US and UK, where she held various international executive leadership positions in international companies.

When the UFS acquired a 100% shareholding in Farmovs earlier this year, she came full circle, as she returned to Bloemfontein to spearhead the expansion of patient studies in collaboration with the Faculty of Health Sciences.

“The opportunities we have here are really enormous,” says an excited Michelle.

“We are the only university in the country with this kind of infrastructure. Apart from our state-of-the-art bioanalytical lab, we also have facilities to accommodate close to 100 research participants. We now have 45 years’ experience in advanced medical research, plus established international clients. We can provide pharmaceutical companies with basically everything they need to develop new medicines.”

Another exciting development is that they are expanding their clinical-trial patient population next year from healthy individuals to people suffering from a host of chronic conditions.

“While they are part of our clinical trials, patients gain valuable insight in their own conditions. We also sometimes pick up underlying medical issues they were not even aware of,” says Michelle.

The 150 Farmovs staff members range from doctors and nurses, to technologists, medical writers, and managers. While not technically part of the university staff, they form a valued part of the Bloemfontein Campus community.

News Archive

DiMTEC gets learnership of R5,7 million
2008-05-23

 

The Disaster Management Training and Education Centre for Africa (DiMTEC) at the University of the Free State (UFS) received a learnership to the value of R5,7 million for the master’s degree programme in Disaster Management for 2008 and 2009 . The learnership programme is funded by the national Department of Science and Technology and DiMTEC is the implementing agent. The learnership makes provision for the study costs and an allowance for 15 students in 2008 and 20 students in 2009. Students are placed at disaster management centres and departments who deal with disaster management across the country where they obtain in-service training on how to effectively deal with disasters. This is the only learnership of its kind in the country. At the hand-over ceremony were, from the left: Mr Andries Jordaan, Director: DiMTEC, Prof. Teuns Verschoor, Acting Rector of the UFS, and Mr Jerry Madiba, Director: Technical Skills, Department of Science and Technology.
Photo: Lacea Loader

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept